Cullinan Management (CGEM) has provided an announcement.
Cullinan Therapeutics has released promising initial data from its Phase 2b REZILIENT1 trial evaluating the effectiveness of zipalertinib for patients with a particular type of lung cancer. The drug, tested in patients previously treated with amivantamab, showed comparable anti-tumor activity to earlier phases of research, with a manageable safety profile and no severe adverse events. The company continues to investigate zipalertinib in various clinical trials, aiming to complete enrollment for pivotal studies by the end of 2024.
See more insights into CGEM stock on TipRanks’ Stock Analysis page.
